fa اثرات پیامدهای تجویز داخل تراشه سوروانتا به اضافه بودزوناید در مقایسه با سوروانتا در نوزادان نارس مبتلا به سندروم زجر تنفسی پزشکی- کودکان Medicine - Pediatric پژوهشي اصیل Original Research <span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">زمینه و هدف: </span></span></b><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">جهت کنترل عوارض در</span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar=""> نوزادان مبتلا به</span></span> <span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">سندرم زجر تنفسی، سورفاکتانت و داروهای کمکی مانند </span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">بودزوناید </span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">مورد استفاده قرار میگیرند تا </span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">واکنش های التهابی مجاری هوایی را کاهش دهند.</span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar=""> هدف از این بررسی تاثیر تجویز داخل تراشه ای </span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">سوروانتا</span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">،</span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar=""> و </span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">سوروانتا</span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar=""> + بودزوناید در نوزادان نارس مبتلا به سندرم زجر تنفسی است.</span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">مواد و روش ها: </span></span></b><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">در این کارآزمایی بالینی، </span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">50 نوزاد نارس مبتلا به سندرم زجر تنفسی، بستری در بخش مراقبت های ویژه نوزادان، بیمارستان کودکان قزوین، در سال 1399، در دو گروه تجویز داخل تراشه &shy;ای </span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">سوروانتا</span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar=""> (1 میلی لیتر) </span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">+ بودزوناید (0/25&nbsp;</span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">میلی گرم) (25 مورد) و سوروانتا (25 مورد) بررسی شدند. از </span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">نرم افزار 21 &nbsp;</span></span><span dir="LTR" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">SPSS</span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar=""> جهت انجام آمار توصیفی، و از آزمون تی و دقیق فیشر جهت آنالیز داده ها استفاده شد (0/05></span></span><span dir="LTR" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">p</span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">).</span></span><span lang="FA" style="font-size:12.0pt"><span style="font-family:"B Zar""></span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">یافته ها:</span></span></b><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar=""> در گروه گیرنده سوروانتا+بودزوناید تنها پیامد ها، خونریزی داخل بطنی و مرگ و میر ( هرکدام50%) بودند. در گروه سن حاملگی بیش از 31 سال و نوزادان دختر دریافت کننده سوروانتا+ بودزوناید، هیچ پیامدی دیده نشد. اثربخشی سوروانتا+ بودزوناید در مقایسه با سوروانتا در کاهش عوارض و پیامدها در نوزادان (0/048 =</span></span><span dir="LTR" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">p</span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">)، </span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">بر حسب </span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">گروه سنی 31 سال و کمتر </span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">از 31 سال </span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">(0/049=</span></span><span dir="LTR" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">p</span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">) و بیشتر از 31 سال (0/046=</span></span><span dir="LTR" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">p</span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">)، دختران (0/047=</span></span><span dir="LTR" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">p</span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">) و پسران (0/050=</span></span><span dir="LTR" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">p</span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">) تفاوت معناداری داشت.</span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:0in 35.4pt"><span style="direction:rtl"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">نتیجه گیری: </span></span></b><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">تجویز سوروانتا همراه با بودزوناید، </span></span><span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">اثربخشی بهتر و عوارض کمتری را به همراه داشت. از </span></span><span lang="FA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">بودزوناید به عنوان یک درمان کمکی می توان استفاده نمود.</span></span> <span lang="AR-SA" style="font-size:12.0pt"><span b="" style="font-family:" zar="">اقدامات درمانی مناسب جهت بهبود و زنده نگه داشتن نوازادان با سندروم زجر تنفسی حائز اهمیت است. </span></span></span></span></span></span></span></span><br> <br> &nbsp; <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Background and Aim: </span></span></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">To control complications in infants with respiratory distress syndrome, surfactants and auxiliary drugs such as budesonide are used to reduce the inflammatory reactions of the airways. The aim of this study is to compare<b> </b>the effect of intratracheal administration of </span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">survanta</span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> and survanta with budesonide in premature infants with respiratory distress syndrome.</span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Materials and Methods:</span></span></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">This clinical trial included 50 premature infants with respiratory distress syndrome, hospitalized in the neonatal intensive care unit in Qazvin Children&#39;s Hospital, in 2019. The patients were divided into two groups. One group (25 cases) received intratracheal survanta (1 milliliter) + budesonide (0.25 milligram) and the other group (25 cases) received only intratracheal survanta. Using SPSS 21 software, data were analyzed by &nbsp;descriptive statistics, Fisher&#39;s exact and T-test (p<0.05).</span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:20.05pt center 207.65pt"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Results:</span></span></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> In the </span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">survanta</span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">+budesonide group, we found intraventricular hemorrhage in 50% and also death in 50% of the cases. In the pregnant women over 31 years of age and female infants receiving </span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">survanta</span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> + budesonide, no complications were seen. The effect of Survanta + budesonide compared to </span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">survanta</span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> on reducing complications in the infants (p = 0.048), in regard to the mothers&#39; age group; 31 years and under 31 </span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">years </span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">(p = 0.049), and over 31 years of age (p = 0.046), female (p=0.047) and male (p=0.050) showed &nbsp;significant differences.</span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:20.05pt center 207.65pt"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Conclusion:</span></span></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Administering survanta with budesonide resulted in better efficacy and fewer side effects. Budesonide can be used as an adjuvant treatment. Appropriate therapeutic measures are important for the improvement and survival of the newborns with respiratory distress syndrome.</span></span></span></span></span></span> سوروانتا, بودزوناید, نوزادان نارس, سندروم زجر تنفسی Surfactant, Surfactant with budesonide, Premature infants, Respiratory distress syndrome 48 64 http://sjku.muk.ac.ir/browse.php?a_code=A-10-6725-1&slc_lang=fa&sid=1 Morteza Habibi مرتضی حبیبی drmhabibi@yahoo.com 5400319475328460060351 5400319475328460060351 No Children Growth Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. مرکز تحقیقات رشد کودکان، پژوهشکده پیش گیری از بیماری های غیر واگیر، دانشگاه علوم پزشکی قزوین، قزوین، ایران Fatemeh Toohidinia فاطمه توحیدی نیا dr.fatemetoohidnia@gmail.com 5400319475328460060352 5400319475328460060352 Yes Children Growth Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. مرکز تحقیقات رشد کودکان، پژوهشکده پیش گیری از بیماری های غیر واگیر، دانشگاه علوم پزشکی قزوین، قزوین، ایران